Analyzing Korro Bio (NASDAQ:KRRO) and Celldex Therapeutics (NASDAQ:CLDX)

Celldex Therapeutics (NASDAQ:CLDX) and Korro Bio (NASDAQ:KRRO) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares Celldex Therapeutics and Korro Bio”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54 million	1,419.15	-$258.76 million	($4.35)	-6.40
Korro Bio	$2.38 million	54.90	-$117.26 million	($10.00)	-0.89

Korro Bio has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Celldex Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Korro Bio has a beta of 3.13, meaning that its share price is 213% more volatile than the S&P 500.

Institutional & Insider Ownership

13.2% of Korro Bio shares are owned by institutional investors. 5.2% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Korro Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Celldex Therapeutics and Korro Bio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1	1	11	1	2.86
Korro Bio	1	2	6	3	2.92

Celldex Therapeutics presently has a consensus price target of $61.92, suggesting a potential upside of 122.50%. Korro Bio has a consensus price target of $16.50, suggesting a potential upside of 85.81%. Given Celldex Therapeutics’ higher possible upside, research analysts clearly believe Celldex Therapeutics is more favorable than Korro Bio.

Profitability

This table compares Celldex Therapeutics and Korro Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-52.35%	-47.61%
Korro Bio	N/A	-114.26%	-68.57%

Summary

Celldex Therapeutics beats Korro Bio on 7 of the 13 factors compared between the two stocks.

About Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

About Korro Bio

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.